1. Introduction
===============

Breast cancer is a worldwide health problem that affects a larger number of women. Global Cancer Statistics reported that more than 1.6 million women were diagnosed with breast cancer in 2012 ^\[[@R1]\]^. The incidence and mortality of breast cancer are increasing in China, where it is now the leading cause of cancer death in women younger than 45 years ^\[[@R2]\]^. Although the causes of breast cancer are unclear, some studies have reported the pathogenesis of the disease to be influenced by genetic factors. Known genetic factors include rare variants; moderate to high penetrance of Breast Cancer gene 1(BRCA1), Breast Cancer gene 2 (BRCA2), partner and localizer of BRCA2 (PALB2), ataxia-telangiectasia mutated (ATM), and checkpoint kinase 2 (CHEK2) and more than 90 common polymorphisms with low penetrance ^\[[@R3]--[@R10]\]^.

The claudin 10 (*CLDN10*) gene has the cytogenetic location 13q32.1 and encodes a member of the claudin family. Claudins are integral membrane proteins comprising tight junction strands. Tight junction strands serve as physical barriers to prevent solutes and water from passing through epithelial and endothelial cell sheets and play a key role in maintaining cell polarity and signal transductions. Previous studies have shown that the expression level of *CLDN10* is associated with thyroid carcinoma, primary hepatocellular carcinoma and lung adenocarcinoma ^\[[@R11]--[@R13]\]^. In addition, Na He et al reported a case-control study in China which demonstrated that a *CLDN10* polymorphism (rs1325774) is associated with stage I breast cancer risk, although they failed to verify this relationship in the stage II case-control study ^\[[@R14]\]^. The genetic effect of the rs1325774 polymorphism with regards to breast cancer susceptibility is still unclear.

Our study aimed to investigate the association between *CLDN10* polymorphisms (rs1325774, rs7333503 and rs3751334) and breast cancer risk in South Chinese women, and to analyse the relationship between its mutation and the clinical and pathological features of patients.

2. Materials and methods
========================

2.1. Study design
-----------------

The present study design was based on the case--control study and general characteristics of participants as described in a previously published paper. ^\[[@R15]\]^. The case--control study was conducted in the First Affiliated Hospital of Guangxi Medical University from 2013 to 2015. Participants were Chinese women aged 21 to 74 years. Breast cancer was confirmed by a pathologist, based on immunohistochemical staining. To reduce the potential confounding factors and biases, the following exclusion criteria were used:

1.  patients with secondary tumours or other malignant neoplasms and

2.  the presence of severe infectious diseases.

During the same period, healthy individuals without breast cancer who had attended a check-up at the hospital were enrolled as controls and matched with cases. Both breast cancer patients and healthy controls were randomly selected. A total of 104 breast cancer patients and 118 healthy controls were recruited in this study.

Before recruitment, written consent was obtained from each study subject and the study was approved by the Ethical Review Committee of Guangxi Medical University.

2.2. Data collection
--------------------

Data collection was carried out at the Medical Centre in the First Affiliated Hospital of Guangxi Medical University. Demographic information (age, ethnicity) and health statuses (menarche age and menopause status) were collected through face-to-face interviews. Anthropometric parameters (height and weight) were measured by trained personnel based on standardised protocols. Body mass indices (BMI) were calculated as weight divided by height squared (kg/m^2^). Clinical data (metastasis distance, molecular classification and pathology type) of patients were obtained from medical records. The intrinsic subtypes of breast cancer included Luminal A subtypes, Luminal B1, Luminal B2, HER-2 overexpressing, and triple-negative. The pathology type was classified into ductal, lobular and other based on the pathological result.

2.3. DNA extraction and genotyping
----------------------------------

Genomic DNA was extracted from whole blood samples using a genomic DNA isolation kit (Sangon Biotech, Shanghai, China) according to the manufacturer\'s instructions. The SNPscan system (Genesky Biotechnologies Inc., Shanghai, China) was used for genotyping. This system has been reported in detail elsewhere (<http://biotech.geneskies.com/en/index.php/Index/fuwuer/id/29>). Briefly, the technology is a multi-gene mutation screening method, which improves the multiplex ligation-dependent probe amplification technology. Four different fluorescent dyes and lengths of ligations were applied in order to detect multiple SNPs simultaneously in 1 reaction. Quality control assessment was performed during genotyping to ensure accuracy. The samples were blinded to laboratory personnel and blank controls were used for all PCR amplifications. Finally, 10% of samples from the subjects were randomly selected for evaluation of quality of genotyping, which showed 100% concordance. The sequences of specific ligase probes are presented in Table [1](#T1){ref-type="table"}.
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Primers used for this study.
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3. Statistical analysis
=======================

All data were recorded as Microsoft Excel files and analysed using Statistical Package for Social Sciences program (SPSS) version 22.0 software (IBM, São Paulo, Brazil). The Hardy--Weinberg equilibrium (HWE; *P* \>.05) was performed using SHEsis (<http://analysis.bio-x.cn/myAnalysis.php>) ^\[[@R16],[@R17]\]^. Gene Expression Profiling Interactive Analysis (GEPIA) ([http://gepia.cancer-pku.cn](http://gepia.cancer-pku.cn/)) was used to analyse the expression of *CLDN10* in breast cancer tissues and normal sample ^\[[@R18]\]^. Briefly, GEPIA is a web-based tool that provides fast and customisable functionalities for research based on The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) data. Differential expression analysis, profiling plotting, correlation analysis, patient survival analysis, similar gene detection and dimensionality reduction analysis can be carried out using GEPIA.

The mean and standard deviation (SD) were used to describe the age variable, and the Student *t* test was used to analyse the difference in ages between the case and control groups. The association between the *CLDN10* polymorphisms (rs1325774, rs7333503, and rs3751334) and breast cancer risk, as well as the patients' demographic information and health statuses, were analysed using simple unconditional logistic regression and multiple logistic regression analysis. The Chi-square test (*X*2) or Fisher exact test was applied to calculate the relationship between the rs1325774 polymorphism and tumour characteristics. A *P* value \<.05 was considered statistically significant.

4. Result
=========

4.1. The association between *CLDN10* rs1325774, rs7333503 and rs3751334 polymorphisms and the susceptibility to breast cancer
------------------------------------------------------------------------------------------------------------------------------

Of the selected study participants, 6 control subjects were removed due to genotyping failure. The genotype frequencies of the controls were in accordance with the Hardy-Weinberg equilibrium. The association between the 3 *CLDN10* polymorphisms studied and breast cancer risk is shown in Table [2](#T2){ref-type="table"}. A frequency of disease of 24.1% was observed for the rs1325774 T/G genotype, and the distribution of the T/G genotype in patients and healthy controls was 32 and 20 respectively. The G/G genotype was not detected in healthy controls. According to simple unconditional logistic regression, the rs1325774 T/G genotype was significantly associated with an increased risk of breast cancer (T/G vs. T/T: OR = 2.073, 95% CI = 1.095--3.927, *P* = .025).
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Association between CLDN10 polymorphisms (rs1325774, rs7333503, rs3751334) and breast cancer risk.
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After adjusting for age, associations between the T/G genotype of rs1325774 and breast cancer remained statically significant (OR = 2.067, 95% CI = 1.070--3.867, *P* = .026). Furthermore, the G allele of rs1325774 was significantly associated with an increased risk of breast cancer (OR = 1.993, 95% CI = 1.107--3.589, *P* = .022).

In this study, no significant association between rs7333503 or rs3751334 and breast cancer was observed.

4.2. Lack of association between rs1325774 polymorphism of *CLDN10* and clinical characteristics in breast cancer patients
--------------------------------------------------------------------------------------------------------------------------

To understand the association between the rs1325774 polymorphism of *CLDN10* and clinical risk factors, we analysed the clinical data including demographic information, health status and clinical data. No parameters were significantly associated with the polymorphism and subset analysis did not indicate any significant result (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Therefore, no association was seen between the rs1325774 polymorphism of *CLDN10* and clinical characteristics of breast cancer.
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Association analysis between CLDN10 rs1325774 and subgroups of 104 patients with breast cancer.
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The relationship between rs1325774 polymorphism and tumor characteristic.
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4.3. Expression of *CLDN10* is reduced in breast cancer tissues
---------------------------------------------------------------

Analysis of matched normal tissue from TCGA database using GEPIA indicated that the expression level of *CLDN10* in breast cancer tissues (n = 1085) was reduced compared with normal tissues (n = 112) (Fig. [1](#F1){ref-type="fig"}A). The expression body map analysed by normalising to transcripts per million (TPM) revealed the median expression of *CLDN10* to be reduced in breast cancer tissues compared with normal samples, with numerical values of 0.21 and 0.88 respectively (Fig. [1](#F1){ref-type="fig"}B).

![The median expression level of CLDN10 gene in normal and breast cancer tissues by GEPIA. The GEPIA indicated that the expression level of CLDN10 in breast cancer tissues (n = 1085) was reduced compared with normal tissues (n = 112) based on TCGA data (Figure 1A). The median expression of CLDN10 to be reduced in breast cancer tissues compared with normal samples based on the expression body map analysed through normalising to TPM, with numerical values of 0.21 and 0.88 respectively (Figure 1B). GEPIA = Gene Expression Profiling Interaction Analysis, TPM = transcripts per million.](medi-97-e13187-g005){#F1}

5. Discussion
=============

Breast cancer is one of the most widespread malignancies in females ^\[[@R1],[@R19]\]^, and genetic effects can have important influences on the occurrence of the disease. In this study, we aimed to evaluate the relationship between 3 SNPs of CNDL10 and breast cancer, as well as relationship of the SNPs to the clinical characteristics of the patients. Our study involved 104 breast cancer patients and 112 healthy controls and found that the rs1325774 polymorphism was significantly associated with an increased risk of breast cancer. No significant association was observed between the rs7333503 or rs3751334 polymorphisms and breast cancer. Expression of *CLDN10* was reduced in breast cancer tissues compared with normal breast tissues according to the analysis of matched normal tissue from TCGA using GEPIA ^\[[@R18]\]^.

There are some limitations in our study: First, our study has selection bias because our subjects recruited from the same hospital. Second, with the limited sample size and statistical power (\<80%), the *P* value was only considered significant at the .05 level, which may affect the results of stratified analysis. Further studies are needed to confirm the influence of the rs1325774 polymorphism on breast cancer based on larger populations. Third, our study did not elucidate the mechanism of pathology. Further functional studies are required to reveal the molecular mechanism of rs1325774-promotion of breast cancer.

Previous studies have reported that the level of *CLDN10* expression is associated with hepatocellular carcinoma, thyroid carcinoma and lung adenocarcinoma ^\[[@R11]--[@R13]\]^. Human *CLDN10* expression is associated with cancer progression---when *CLDN10* is overexpressed in patients with lung adenocarcinoma, a good prognosis for overall survival is reported ^\[[@R13]\]^. However, it is not clear whether SNPs located in different regions of *CLDN10* are associated with the risk and clinical characteristics of breast cancer.

Na He et al previously reported that rs1325774, located in the microRNA binding site in the seed region of the 3'-UTR of *CLDN10*, is significantly associated with an increased risk of breast cancer in a large case-control study which included genome-wide microRNA binding site SNPs in stage I ^\[[@R14]\]^. The results of the present study are consistent with those of Na He et al.

The study of SNPs at miRNA target sites has attracted attention. It has been reported that genetic changes in the 3'-UTR of transcribed genes can alter the affinity between miRNA and mRNA. Therefore, these single nucleotide mutations can change the levels of protein expression through manipulation of the interactions between miRNA and their target sequences ^\[[@R20]--[@R23]\]^. It can be hypothesised that miRNA-related SNPs may be a factor in the occurrence of breast cancer.

Huiyan Sun et al reported that miR-486 functions as a novel tumour suppressor miRNA in hepatocellular carcinoma (HCC) by targeting *CLDN10*. By regulating the expression of this gene, miR-486 inhibits proliferation and migration of hepatoma cells and functions. It has been reported that *CLDN10* dominantly contributes to the suppressive effect of miR-486 on the epithelial-mesenchymal transition (EMT) of hepatocellular carcinoma cell ^\[[@R11]\]^. Currently, 8 miRNAs that can target *CLDN10* are detailed in miRTarBase. In regards to the specific function of *CLDN10* in breast cancer development and progression, we hypothesise that rs1325774 affects the binding affinity of miRNAs and thus affects the occurrence of breast cancer by regulating the expression of *CLDN10*.

In conclusion, our results demonstrate the relationship between the rs1325774 polymorphism of *CLDN10* and the risk of breast cancer. This finding is consistent with the large case-control study of Han Chinese women with stage I breast cancer. Together, the 2 studies suggest that rs1325774 may be a biomarker for breast cancer predisposition. Further functional studies are needed to identify the exact role of rs1325774 in the occurrence of breast cancer.
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